Latest news with #FieldMedical
Yahoo
02-07-2025
- Business
- Yahoo
Field Medical raises $35m to advance ablation system development
Field Medical has closed a $35m series B financing round for advancing the development of the FieldForce pulsed field ablation platform. This round was co-led by BioStar Capital and Cue Growth, with contributions from current strategic investors. The funds will also facilitate the launch of the pivotal VERITAS trial and strengthen the company's clinical and regulatory capabilities. It brings Field Medical's total funding to $75m. BioStar Capital founder and senior managing director Dr Louis Cannon said: 'Field Medical's transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency. 'Their physician-led team brings the right insight, and their FieldForce platform brings the right tools.' In 2024, the FieldForce ablation system received breakthrough device designation and was selected for the US Food and Drug Administration (FDA) TAP Pilot programme for ventricular tachycardia (VT). The next-generation system has been designed for transmural lesion creation and provides a new approach to VT ablation. It remains an investigational device, limited to research use under US law. Field Medical founder and CEO Dr Steven Mickelsen said: 'VT is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need. 'We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.' In conjunction with this growth funding, Field Medical has updated its board of directors. The board includes Dr Steven Mickelsen, the company's founder and CEO; Mark Wisniewski, CFO of Enterra Medical; and Marlou Janssen, board member at Field Medical, Sonion, Acarix, EBAMed and Inspiration Healthcare. Additional members comprise surgeon and entrepreneur Alexei Mlodinow and Cue Growth founding partner Ben Cannon. "Field Medical raises $35m to advance ablation system development" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Malaysian Reserve
22-04-2025
- Business
- Malaysian Reserve
FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA
CARDIFF-BY-THE-SEA, Calif., April 21, 2025 /PRNewswire/ — Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million in new capital and the conversion of $20 million in seed-round debt. Participants include several leading strategics, venture capital firms and family offices, with multiple seed investors reinvesting – underscoring strong confidence in the company's initial focus on ventricular tachycardia (VT) and the broader versatility of its technology. The funding will support the completion of two pilot studies – VCAS for VT and Field PULSE for atrial fibrillation (AF) – as well as continued development of Field's commercial PFA system and operational scale-up in preparation for VERITAS, the company's pivotal trial focused on VT. 'This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy,' said Steven Mickelsen, M.D., founder and chief executive officer of Field Medical. 'With the support of our investors, we are accelerating the development of the FieldForce™ Ablation System, building on early clinical evidence, and moving closer to our commercial goal of expanding access to next-generation PFA solutions for cardiac ablation.' 'We are encouraged by the strong support and confidence from both new investors and our reinvesting seed-round investor base,' said Oskar Dadason, chief financial officer. 'This funding enables us to execute our strategic plan with speed and focus as we transition from early-stage innovation into commercial readiness.' Field Medical is developing transformative technology for the treatment of all cardiac arrhythmias, including VT and AF. The FieldForce Ablation System, featuring the first built-for-purpose, contact force focal PFA catheter, enables an instantaneous ablation workflow, with therapy delivered in a fraction of a second. Recent results from the VCAS (VT) and PULSE (AF) pilot studies demonstrate the system's versatility. Powered by FieldBending™, the company's proprietary technology that delivers brief, high-intensity electric fields, the System is positioned as the single, advanced solution for treating a full spectrum of cardiac arrhythmias. About Field Medical® in 2022, Field Medical is advancing next-generation pulsed field ablation (PFA) technologies to address the complex needs of modern cardiac ablation. The company is led by Dr. Steven Mickelsen, a pioneer in pulsed electric field technology and a leading innovator in the field. His foundational work in PFA established the basis for modern advancements in the technology, which Field Medical continues to refine with its groundbreaking solutions. In 2024, Field Medical's technology was recognized by the FDA with Breakthrough Device Designation and inclusion in the TAP Pilot Program. For more information, visit and follow us on LinkedIn and X. The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use. The Growing Prevalence of VT and AFVentricular tachycardia (VT) and atrial fibrillation (AF) are two of the most common and serious arrhythmias, contributing to stroke, heart failure, sudden cardiac death and escalating health care costs. VT and premature ventricular contractions (PVCs) affect more than 6 million people in the United States and Europe, while AF impacts an estimated 2% to 6% of the global population. The AF catheter ablation market is currently valued at $5 billion and is projected to grow at a compound annual growth rate of 13% to 16%, surpassing $11 billion by 2034. In comparison, the global VT market— which includes devices and catheter ablation—was valued at approximately $12.5 billion in 2021 and is expected to grow at a compound annual growth rate of 5.26%, reaching $17 billion by 2027. Notably, the catheter ablation segment within the VT treatment market is projected to grow at a higher rate of 13% annually during this period, reflecting increased adoption of catheter-based interventions for VT management. Media ContactHolly Windler619.929.1275
